Abstract | BACKGROUND: METHODS: AA was induced in 6-8 rats per group. MTX was administrated twice a week at a dose of 0.3 mg/kg b.w., while CA was administered daily at a dose of 100 mg/kg both in monotherapy and in combination with MTX. Plasma samples were collected on the 14th, 21st, and 28th day. Body weight and hind paw volume were measured once a week. RESULTS: We found that, mainly, the CA + MTX combination significantly reduced the hind paw swelling, the levels of IL-17A, MMP-9, and MCP-1 in plasma, and GGT activity in joint homogenates. The mRNA expression of HO-1, catalase, and IL-1β in the liver were significantly improved by CA + MTX only. Our results indicate that adding CA to MTX treatment could be a good therapeutic option for patients suffering from RA. CONCLUSIONS: The addition of CA to methotrexate treatment significantly improved its efficacy in decreasing the development of AA by inhibiting the markers of inflammation and oxidative stress.
|
Authors | Martin Chrastina, Silvester Poništ, Jaroslav Tóth, Szilvia Czigle, Ľudmila Pašková, Veronika Vyletelová, Karol Švík, Katarína Bauerová |
Journal | Molecules (Basel, Switzerland)
(Molecules)
Vol. 27
Issue 20
(Oct 21 2022)
ISSN: 1420-3049 [Electronic] Switzerland |
PMID | 36296709
(Publication Type: Journal Article)
|
Chemical References |
- Methotrexate
- Interleukin-17
- Matrix Metalloproteinase 9
- salvin
- Catalase
- Biomarkers
- RNA, Messenger
|
Topics |
- Rats
- Animals
- Methotrexate
- Arthritis, Experimental
(drug therapy)
- Interleukin-17
(metabolism)
- Matrix Metalloproteinase 9
(metabolism)
- Catalase
(metabolism)
- Drug Therapy, Combination
- Arthritis, Rheumatoid
(drug therapy)
- Oxidative Stress
- Biomarkers
(metabolism)
- Inflammation
(drug therapy, metabolism)
- RNA, Messenger
(metabolism)
|